How choice of reactor vessel affects reaction performance
New report compares the thermal performance and advantages of vacuum jacketed versus non-vacuum jacketed reaction vessels.
Asynt has produced a new report that compares the thermal performance and advantages of vacuum jacketed versus non-vacuum jacketed reaction vessels.
Data is presented for vacuum jacketed and non-vacuum jacketed reaction vessels connected to a Julabo Presto A30 temperature control system. The report demonstrates that a vacuum jacketed vessel not only achieved faster rates of cooling but was also able to maintain a reaction at -20 °C compared with just -15 °C for the non-vacuum jacketed vessel. Using a vacuum jacketed vessel was also shown to eliminate ice formation on the outside of the reactor glass (a common problem with non-vacuum jacketed reaction vessels), allowing continuous viewing of the reactor contents.
By reducing heat loss/gain a glass vacuum jacket enables faster rates of heating and uses less energy to cool the system, thereby enabling lower temperatures to be achieved than reactor vessels without a vacuum jacket. The report concludes that using a vacuum jacketed reaction vessel will allow users to optimise thermal performance thereby improving control of reactions. In addition, the report proposes that the small additional cost of a vacuum jacketed vessel is easily justified not only by the additional performance but also by the cost saving of being able to use a lower powered temperature control system.
Vacuum jacketed reaction vessels are available as options for the Asynt ReactoMate Pilot (5-50 L) and for the Asynt ReactoMate Datum (100 mL - 5 L) reactor systems.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.